NRAS and acute myeloid leukemia: We then estimated the odds ratios of driver mutations including NRAS selected by a L1-regularized logistic regression model to assess their impact on the pCMML/dCMML phenotype, LT risk, OS, and AML-FS (Fig. 1H, I).